The last participant has completed all predefined assessments in the Phase 3 COGNITE clinical trial, which is assessing the safety and effectiveness of AZTherapies’ treatment candidate ALZT-OP1 for people with early Alzheimer’s disease. The trial’s top-line results are expected in the first months of 2021. The biopharmaceutical company hopes its investigational therapy will be found to slow or even stop the progression of Alzheimer’s. “We will soon begin data analysis, bringing us one step closer…
You must be logged in to read/download the full post.
The post Last Patient Finishes ALZT-OP1 Combo Therapy Trial; Results Expected Early 2021 appeared first on BioNewsFeeds.